Gefitinib has the potential of activating cell immunity against malignant cells.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 23 ·No. 16 ·2005-06-01 ·Pages 3865-6; author reply 3866-7

Kanazawa S, Muramatsu M, Kinoshita Y, Yamaguchi K, Nomura S

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/therapeutic use Biomarkers, Tumor/metabolism Carcinoma, Non-Small-Cell Lung/drug therapy,immunology,metabolism ErbB Receptors/antagonists & inhibitors,metabolism Gefitinib Humans Immunity, Cellular Lung Neoplasms/drug therapy,immunology,metabolism Quinazolines/therapeutic use

Chemicals

Antineoplastic Agents Biomarkers, Tumor Quinazolines ErbB Receptors Gefitinib

Authors & Affiliations

5 authors, click to expand affiliations / ORCID

Kanazawa Shigenori

Muramatsu Mikiko

Kinoshita Yoshimi

Yamaguchi Kazuyuki

Nomura Shosaku

Article Info

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Abbr.

J Clin Oncol

ISSN

0732-183X

DOI

10.1200/JCO.2005.05.148

Published

2005-06-01

Pages

3865-6; author reply 3866-7

Language

English

Region

United States

NLM ID

8309333

Subset

Corrections

CommentOn

PMID: 15143103

External Links

PubMed source DOI: 10.1200/JCO.2005.05.148 View journal details

Analysis Services

Gefitinib has the potential of activating cell immunity against malignant cells.

Contact

WeChat Official Account